Sign in
TCRX Stock Price, Chart, Stats & News
TScan Therapeutics, Inc.
Save
56.99M
Market cap
–
Current P/E
–
Forward P/E
TCRX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 85.57% |
Operating margin | -1315.38% |
Pretax margin | -1256.81% |
Net margin | -1256.81% |
Effective tax rate | – |
ROA | -56.72% |
ROE | -79.36% |
D/E | 0.76x |
Interest coverage ratio | -49.05x |
TCRX valuation
P/E | – |
P/S | 5.45x |
P/B | 1.04x |
P/CF | -0.95x |
P/FCF | -0.40x |
P/OCF | -0.95x |
PEG | -0.09x |
EV multiple | -0.86x |
About
TScan Therapeutics, Inc. is a biopharmaceutical enterprise, currently in its preclinical development stage, focused on engineering T cell receptor (TCR) therapies to combat various cancers. The company's pipeline features programs like TSC-100 and TSC-101, which are engineered to address blood cancers by clearing remnant leukemia cells and averting disease recurrence following hematopoietic stem cell transplantation. Additionally, TScan is advancing multiple candidates, including TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, targeting solid tumor indications.
Similar securities
Based on sector and market capitalization
Report issue